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M1 and M2 are the extremes of the differentiation spectrum of activated macrophages. Since microglia are
members of the same cell lineage, we have characterized their transcription proﬁle and their phagocytic
activity under different conditions. LPS or IFN-γ induce a M1-like phenotype, while IL-10 or IL-4 differentiate
microglia towards a M2-deactivated or M2-alternatively-activated phenotype respectively. These differ-
entiation processes also affect the Notch pathway. In order to study the polarization induced by Aβ, microglia
was stimulated with different forms of the peptide. The oligomeric Aβ is a stronger M1-inductor than the
ﬁbrillar form. Moreover, a cytokine-induced anti-inﬂammatory environment reduces the microglial reactivity
towards oligomeric Aβ.
© 2009 Elsevier B.V. All rights reserved.
1. Introduction
Although the ontogeny of microglial cells has long been unclear,
microglia are now recognized as the tissue macrophages of the central
nervous system (CNS) (Kreutzberg,1996). Their density is comparable
to that of Kupffer cells, the tissue macrophages of the liver (Lawson
et al., 1990). However, microglia present a number of characteristics
that distinguish them from other tissue macrophages. With their long
processes, which can be maintained in vitro (Giulian et al., 1995), they
perform a continuous surveillance of the brain parenchyma (Davalos
et al., 2005; Nimmerjahn et al., 2005). They also seem to express a less
mature phenotype than other tissue macrophages. Microglia easily
proliferate in response to a M-CSF exposure (Alliot et al., 1991), and
they express the CD34 progenitor marker (Ladeby et al., 2005). Their
antigen-presenting abilities are poorly developed (Carson et al., 1998).
Nevertheless, like macrophages, microgliocytes are able to react to
tissue insults by a rapid differentiation process leading towards a fully
activated microglial cell showing numerous similarities to any other
activated macrophage (Hanisch and Kettenmann, 2007).
Cells belonging to the monocyte–macrophage lineage are hetero-
geneous. Macrophage heterogeneity is likely to reﬂect the plasticity and
versatility of these cells in response to exposure to microenvironmental
signals. Alternative polarized activation modes of these cells can be
distinguished (Gordon, 2003; Mosser, 2003). Whereas classical activa-
tion of macrophages by microbial compounds or pro-inﬂammatory
cytokines yields a phenotype called M1 that is hallmarked by the
production of pro-inﬂammatory cytokines and free radicals like nitric
oxide and superoxide anions, alternative activation can lead to a less
well deﬁned anti-inﬂammatory phenotype, labeled M2. At least two
differentM2phenotypes have to bedistinguishedbasedupon their gene
expression proﬁle. IL-4 or IL-13 treated macrophages present an
alternative activated phenotype hallmarked by arginase1, Found in
Inﬂammatory Zone 1 (FIZZ1) and chitinase 3-like 3 (Ym1) expression
and by the production of factors involved in tissue remodeling and
wound repair (Raes et al., 2002; Song et al., 2000; Munder et al., 1999).
Macrophages exposed to IL-10 or TGF-β differentiate towards a
deactivated phenotype showing increased CCR2 (Sozzani et al., 1998)
and scavenger receptors (Sulahian et al., 2000). Anti-inﬂammatory
macrophages may evolve by natural neuroendocrine control mechan-
isms and play a role in homeostatic processes, such as dampening
inﬂammation, scavenging debris, angiogenesis and wound healing
(Goerdt et al., 1999; Gordon, 2003).
Functional polarization of macrophages into M1 or M2 cells is an
operationally useful, but a simpliﬁed conceptual framework describ-
ing the plasticity of mononuclear phagocytes. This concept allows a
better understanding of the numerous physiological properties of the
cells belonging to this lineage. Signature genes for both extremes of
the differentiation spectrum have been described for macrophages
(Ghassabeh et al., 2006).
Little is known about the potentials of microglial cells to differentiate
along a similar spectrum of phenotypes. While no doubt remains about
the ability of microglia to react in a pro-inﬂammatory way towards
cytokine stimulation, pattern-recognition receptor ligation or other
danger signals (Blocket al., 2007;Hanisch, 2002), only scarce information
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about alternative activationof these cells is available. ACNS restricted IL-4
deﬁciency exacerbated the clinical symptoms of EAE in a mouse model
(Ponomarev et al., 2007). The same study shows that IL-4 induces the
expression of the alternative activation typical gene Ym1 in brain
macrophages. Microglia that encounter anti-inﬂammatory TH2 cells or
their characteristic cytokines, such as IL-4, are rendered able to support
neuronal survival, oligodendrogenesis and someneurogenesis fromadult
neural progenitor cells (Butovsky et al., 2006). Furthermore,Komohara
et al. recently documented a correlation between M-CSF production by
brain tumors and the anti-inﬂammatory phenotype of the tumor-
inﬁltrating brain macrophages.
The amyloid-β (Aβ) peptide, counting 40 to 42 amino-acids, has a
causal role in Alzheimer's disease (AD) (Snyder et al., 2005). Aβ
peptides have the capacity to self-assemble, passing frommonomeric to
oligomeric, and then to insoluble heavy aggregates, thus progressively
forming the plaques. Oligomeric Aβ, with a molecular weight of around
56 kD, has the most marked toxic effects on the neuronal functions
(Malaplate-Armand et al., 2006), notably impairing memory (Lesne et
al., 2006). This form has also been shown to display the most potent
effect on Long Term Potentiation inhibition (Barghorn et al., 2005). A
causative link with the establishment of the later AD-typical tau
pathology has also been demonstrated (Oddo et al., 2006). It thus
seems well established that the oligomeric form of Aβ plays a crucial
role in the disease onset and progression (Cole and Frautschy, 2006).
In this work, we have studied the signature gene expression and
the phagocytic activity of microglial cells when pushed to both
extremes of the differentiation spectrum M1 and M2. Since several
genes implicated in the Notch pathway are affected by different
inﬂammatory conditions, the inﬂuence of Notch pathway stimulation
on the acquired phenotype is examined. The transcription proﬁle and
the behavior of microglial cells exposed to the different forms of Aβ is
compared to these extremes. The inﬂuence of anti-inﬂammatory
cytokine pathway on this activation process documents a certain
degree of plasticity in the differentiation proﬁle.
2. Materials and methods
2.1. Cell culture
For primarymicroglia, mixed glial cell cultures were prepared from
the brains of newborn C57BL/6 mice as previously described (Morga
et al., 2000). Brieﬂy, after carefully removing meninges and large
blood vessels, the brains were pooled and then minced in cold
phosphate-buffered salt solution. The dissociation was completed by
10 min of incubation in 2 mM EDTA. After washes and centrifugations,
the cells were allowed to attach and grow at 37 °C in DMEM
supplemented with 20% fetal calf serum (FCS) (Invitrogen, Scotland),
penicillin (100 U/mL), and streptomycin (100 μg/mL) in a water-
saturated atmosphere containing 5% CO2. After 4 days, the cells were
moved to 10% FCS-containing DMEM. After 7–10 days, when the
cultures reached conﬂuence, microglia was detached by a 30 min
shaking on a rotary shaker. Detached cells, mainly microglia (N95%),
were then plated in multi-well plates in the same medium.
The murine microglial cell line MMGT12 (Briers et al., 1994), a
generous gift from Dr. Vanmechelen, Innogenetics, Gent (Belgium)
was cultured in DMEM/F12, supplemented with 2% FCS, 1% ITS
(Insulin–Transferrin–Selenium, Invitrogen) and 15% ﬁltered condi-
tioned medium of WEHI cells (WEHI 3, WEHI 3B and WEHI 3D, ATCC,
Rockville, MD) (producer of interleukin-3 and granulocyte-macro-
phage-colony stimulating factor). No antibiotics were used. The cells
were grown at 37 °C in a water-saturated incubator at 5% CO2 and
passaged twice a week. For experiments, MMGT12 cells were seeded
intomulti-well plates at a density of 1×105 cells/well (six-well plates)
or 2×104 cells/well (48-well plates) in DMEM/F12, 10% FCS, 1% ITS
(experimental medium). After 3 days of culture, the cells were
activated adding different stimuli to the culture medium.
Lipopolysaccharide (LPS 055:B5 from Escherichia coli, Sigma,
Belgium) was added at different doses for primary microglia (1 ng/
mL) and MMGT12 (10 ng/mL) to obtain equivalent activation because
of the increased sensitivity of the primary cultures compared to the
cell line. IFN-γ (Hycult Biotechnology, The Netherlands) was used at
100 U/mL, IL-10 and IL-4 (Chemicon, Belgium) were at 1 ng/mL. The
recombinant rat Jagged1/Fc from R&D System (Minneapolis, MN) was
used at 1 μg/mL.
2.2. Real-time reverse transcription-polymerase chain reaction (RT-PCR)
Total RNAwas puriﬁed from cultured cells using the Invisorb® Spin
Cell RNA Mini Kit for total RNA extractions (Invitek, Germany). RNA
analysis was performed with RNA electrophoresis Experion system
(Bio-Rad, CA) to check the quality of RNA and to conﬁrm the absence
of genomic contamination. RNA was reverse transcribed using the
ImProm-II Reverse Transcription System (Promega, CA) with 0.5 μg/
reaction oligo(dT) as primer and 1 μg or 200 ng of total RNA from
MMGT12 microglial cells or primary microglial cells respectively. The
RNA and oligo-dT were denaturated by preheating at 70 °C for 5 min
followed by an immediate chill in ice water for at least 5 min. The
reverse transcription reaction was performed in a total volume of
40 μL containing ImProm-II 5X Reaction Buffer, 25 mM MgCl2, and
0.5 mM of each dATP, dTTP, dCTP, and dGTP for 1 h at 42 °C. Individual
25 μL SYBR Green real-time PCR reactions consisted of 5 μL of cDNA,
12.5 μL of 2X iQ™ SYBR Green Supermix (Bio-Rad), and 1 μL of each
12.5 μM optimized forward and reverse primers in 5.5 μL RNase-free
water.
Primer sequences designed using Beacon Designer software (Bio-
Rad) are described in Table 1.
The PCR was performed on a Bio-Rad iCycler (iQ5 Real Time PCR
Detection System) using a 2-stage program provided by the manufac-
turer: 3 min at 95 °C and 40 cycles of 10 sec at 95 °C and 30 s at 54.5 °C.
For standardization of quantiﬁcation, L27was ampliﬁed simultaneously.
Table 1
Primer list.
Name PCR primer sequences, 5′–3′ GenBank accession no.
1 IL-1β GCT-TCA-GGC-AGG-CAG-TAT-C NM_008361
AGG-ATG-GGC-TCT-TCT-TCA-AAG
2 IL-6 ACC-GCT-ATG-AAG-TTC-CTC-TC NM_031168
CT-CTG-TGA-AGT-CTC-CTC-TCC
3 TNF-α GGT-TCT-GTC-CCT-TTC-ACT-CAC NM_013693
T-GCC-TCT-TCT-GCC-AGT-TCC
4 NOS-II AGC-CCT-CAC-CTA-CTT-CCT-G NM_010927
CAA-TCT-CTG-CCT-ATC-CGT-CTC
5 COX-2 GCC-TGG-TCT-GAT-GAT-GTA-TGC NM_011198
G-AGT-ATG-AGT-CTG-CTG-GTT-TGG
6 CCL2 CAC-TCA-CCT-GCT-GCT-ACT-CAT-TC NM_011333
GCT-TCT-TTG-GGA-CAC-CTG-CTG
7 CCL20 ATG-GGT-ACT-GCT-GGC-TCA-C NM_016960
CT-GGA-AGG-AAG-AGG-CGT-CTG
8 CCR2 CTC-AGT-TCA-TCC-ACG-GCA-TAC NM_009915
GA-CAA-GGC-TCA-CCA-TCA-TCG
9 Arginase1 AGA-CAG-CAG-AGG-AGG-TGA-AGA-G NM_007482
CGA-AGC-AAG-CCA-AGG-TTA-AAG-C
10 Mmr AGT-GGC-AGG-TGG-CTT-ATG NM_008625
G-GTT-CAG-GAG-TTG-TTG-TGG
11 Ym(1/2) CAT-TCA-GTC-AGT-TAT-CAG-ATT-CC NM_009892
AGT-GAG-TAG-CAG-CCT-TGG
12 FIZZ1 TGG-AGA-ATA-AGG-TCA-AGG-AAC NM_020509
G-TCA-ACG-AGT-AAG-CAC-AGG
13 PPAR-γ GCA GGA GCA GAG CAA AGA G NM_011146
GGA CAC CAT ACT TGA GCA GAG
14 Notch1 GCA-GGC-AAG-ATG-TTA-ATG-AGT-G NM_008714
A-GGG-CAC-ATA-GGG-CAG-TTC
15 Hes1 GCC-AAT-TTG-CCT-TTC-TCA-TCC NM_008235
G-GTG-ACA-CTG-CGT-TAG-GAC
16 L27 ACA-TTG-ACG-ATG-GCA-CCT-C NM_011289
GC-TTG-GCG-ATC-TTC-TTC-TTG
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The change of reporter ﬂuorescence from each reaction tube was
monitored. The threshold cycle of each gene was determined as PCR
cycles at which an increase in reporter ﬂuorescence above a baseline
signal was observed. The difference in threshold cycles between the
target gene and reference gene (L27) gives the standardized expression
level (dCt). Subtraction of dCt of a deﬁned control condition from dCt
of different conditions gives the ddCt value that was used to
calculate relative expression levels of different conditions with the
formula 2−ddCt. The expression levels of each gene were expressed
as normalized fold expression.
Each sample was tested in triplicate PCR wells and samples
obtained from three independent experiments were used to calculate
the mean±SEM.
2.3. Measurement of the phagocytosis capacity
Volumes of 500 μL of cell suspension (density of 2×104 cells/well)
were seeded into 48-well microtiter plates. After 48 h at 37 °C, the cells
were treated and further incubated during 24 h. Yellow-green Fluo-
Spheres (1 μm, Molecular Probes, CA) were resuspended in 25 mM
Na2HPO4, pH 6.0 containing 3% BSA and incubated at room temperature
for 15 min with bath sonication. The sonicated suspension, containing
108microspheres in 25 μL,was added to culturedmicroglia. After 75min
at 37 °C, cells were washed 3 times with PBS and ﬂuorescence was
measured at 520 nmwith a microplate reader (FLUOstar OPTIMA, BMG
LABTECH, NC). To differentiate between phagocytosed beads and beads
that non-speciﬁcally adhered to the cell surface, control cells were
exposed to 0.3% azide for 10 min before the addition of microspheres.
This treatment compromises microglial energetic processes and few
beads are internalized as observed by ﬂuorescent microscopy. The
ﬂuorescence of azide treated MMGT12 microglial cells was used as the
negative control. Background ﬂuorescence of MMGT12 microglial cells
cultured in the absence ofﬂuorescentmicrosphereswas less than 10% of
the ﬂuorescence values obtained using azide treated MMGT12 micro-
glial cells cultured in the presence of microspheres.
In the same experiments, the luminescent cell viability assay was
conducted to quantify the number of cells per well. The CellTiter-Glo
luminescent cell viability assay (Promega) was used to determine the
number of viable cells in culture.
2.4. Arginase assay
Arginase activity was measured in cell lysates with slight
modiﬁcations, as previously described (Corraliza et al., 1994). Brieﬂy,
Fig. 1. M1-like phenotype in microglial cells. A. MMGT12 and primary microglial cells gene expression proﬁles. Data are representative of three independent experiments. Gene
expression levels were determined by reverse transcription followed by real-time PCR and were normalized with the housekeeping gene L27. The transcription levels were analyzed
after 6 h of incubationwith LPS (10 ng/mL inMMGT12 cells and 1 ng/mL in primarymicroglia) or IFN-γ (100 U/mL). Results (value±SD) are expressed relative to control conditions.
B. Phagocytosis assay. MMGT12 microglial cells were treated with IFN-γ (100 U/mL) during 24 h. Data are corrected for the cell population values and are expressed as mean±SEM
values obtained from three experiments, each conducted in independent cultures (n=3). Results are expressed relative to control (Ctr=100%). ⁎pb0.05, ﬂuorescence levels are
signiﬁcantly different from the corresponding control levels.
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cells were lysed with 150 μL of 0.1% Triton X-100 (Sigma). After 30min
on a shaker, 50 μL of 50 mM Tris–HCl, 10 mM MnCl2 (pH 7.5) were
mixed with 50 μL of lysate and the enzyme was activated by heating
for 10 min at 56 °C. Arginine hydrolysis was conducted by incubating
the lysate with 50 μL of 0.5 M L-arginine (pH 9.7) at 37 °C for 120 min.
The reaction was stopped with 400 μL of H2SO4 (96%)/H3PO4 (85%)/
Fig. 2.M2-like phenotype inmicroglial cells. A.MMGT12 and primarymicroglial cells gene expressionproﬁles. Data are representative of three independent experiments. Gene expression
levels were determined by reverse transcription followed by real-time PCR and were normalized with the housekeeping gene L27. The transcription levels were analyzed after 6 h of
incubationwith IL-10 (1ng/mL) or IL-4 (1ng/mL). Results (value±SD) are expressed relative to control conditions. B. Phagocytosis assay.MMGT12microglial cellswere treatedwith IL-10
(1 ng/mL) or IL-4 (1 ng/mL) during 24 h. Data are corrected for the cell population values and are expressed as mean±SEM values obtained from three experiments, each conducted in
independent cultures (n=3). Results are expressed relative to control (Ctr=100%). ⁎⁎pb0.01, ﬂuorescence levels are signiﬁcantly different from the corresponding control levels. C.
Arginase assay.MMGT12microglial cells were treatedwith IL-10 (1 ng/mL) or IL-4 (1 ng/mL) during 24 h and arginase activitywas determined. Data are expressed asmean±SEMvalues
obtained from three experiments, each conducted in independent cultures (n=3). Results are expressed relative to control (Ctr=0.013 nmol/μg of total proteins/h). ⁎⁎pb0.01, arginase
activity is signiﬁcantly different from the corresponding control level.
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H2O (1/3/7, v/v/v). The urea concentration was measured after
addition of 25 μL 9% α-isonitrosopropiophenone (dissolved in 100%
ethanol) followed by heating at 100 °C for 45 min. Absorbance was
measured at 550 nm in amicroplate reader (TECAN, Austria). One unit
of enzyme activity is deﬁned as the amount of enzyme that catalyzes
the formation of 1 μmol of urea per min.
2.5. Aβ preparation and Thioﬂavine T assay
Aβ1-42 (Bachem, Germany) was dissolved at a concentration of
20 mg/mL (5 mM) in dimethyl sulfoxide. The stock was diluted to
2 mg/mL (0.5 mM) in DMEM/F12 containing 1% antibiotics. The
oligomeric-Aβ (ol-Aβ) was added directly to cultures at a ﬁnal
concentration of 5 μM. The ﬁbrillar-Aβ (f-Aβ) was obtained incubating
the oligomeric form during 2 days at 37 °C and then added to cultures
at the same ﬁnal concentration.
For the Thioﬂavine T assay, the stock of Aβ1-42 was diluted to
0.2mg/mL (50 μM) in PBS and then 100 μL of this solutionweremixed
with 900 μL of 3 μM Thioﬂavine T (in 50 mM potassium phosphate
buffer, pH 6.0). The solution was added to a 96-well plate at 100 μL/
well (n=6). Fluorescence was read at 485 nm using a microplate
reader (FLUOstar OPTIMA).
2.6. Statistical analysis
For comparison of means between two different treatments,
statistical analysiswas done by Student's t-test (two-sample assuming
equal variances). For comparison of multiple treatments, results were
analyzed by an ANOVA followed by a Fisher's exact test.
3. Results
3.1. Characterization of the M1-like state in microglial cells
In an attempt to analyze different pro-inﬂammatory phenotypes,
microglial cells were exposed to LPS (10 ng/mLor 1 ng/mL forMMGT12
or primary microglial cells respectively, according to their response
levels) or IFN-γ (100U/mL). Both stimuli inducedhigh expression levels
of the inﬂammatorycytokines, IL-6 and TNF-α, aswell as the chemokine
CCL2 (Fig. 1A). The expression of genes encoding for the enzymes
responsible for theproductionof free radicals (NOS-II) or prostaglandins
(COX-2)was also enhanced. In contrast to LPS, IFN-γ down regulated IL-
1β and CCL20 transcription levels in MMGT12 and primary microglial
cells compared to the control levels. Moreover, LPS inhibited the M2
signature gene CCR2, while IFN-γ increased it. Arginase1 and Mmr
expression levels were reduced by LPS as well as by IFN-γ.
Since a modulatory role of the Notch pathway during macrophage
activationhasbeendocumented (Monsalve et al., 2006), twocomponents
of this pathway have been undertaken asM1 orM2markers. As shown in
our previous results (Grandbarbe et al., 2007), under inﬂammatory
conditions (LPS or IFN-γ) Notch1 mRNA was raised, while Hes1 was
strongly reduced. In the same conditions, PPAR-γ expression levels,
known to be modulated during inﬂammatory responses (Bernardo and
Minghetti, 2006), were strongly reduced (Fig. 1A).
As the microglial phagocytic activity is inﬂuenced by different
inﬂammatory stimuli (Koenigsknecht-Talboo and Landreth, 2005), the
study of the behavior towards this parameter was deepened. IFN-γ
decreased the MMGT12 phagocytic activity by 46.5% (Fig. 1B), while LPS
hadno inﬂuenceon the capacity to ingestmicrospheres (datanot shown).
3.2. Characterization of the M2-like state in microglial cells
At the opposite side of the spectrum of phenotypes, in order to
study their different anti-inﬂammatory states, microglial cells were
exposed to IL-10 (1 ng/mL) or IL-4 (1 ng/mL).
Microglial cells treated with IL-10 were characterized by a slight
increase of IL-1β, NOS-II, COX-2, and CCL2 expression levels (Fig. 2A).
TNF-αmRNAwas decreased by IL-10 compared to the control levels. IL-
10 was also able to slightly enhance the M2 signature genes, CCR2 and
arginase1. The Notch components and PPAR-γ were not inﬂuenced by
IL-10 treatment.
IL-4 reduced IL-1β and CCR2 expression levels compared to the
control conditions. As IL-10, IL-4 reduced TNF-α mRNA. The transcrip-
tion of the typical “alternative” genes, arginase1, Mmr, Ym(1/2) and
FIZZ1 was strongly enhanced after IL-4 treatment in MMGT12 and
primary microglial cells. The Notch receptor transcription level was
decreased by IL-4, while PPAR-γwas enhanced (Fig. 2A).
The phagocytosis ability was strongly enhanced by IL-10 (168%),
but was not inﬂuenced by IL-4 (Fig. 2B). The arginase assay conﬁrmed
that IL-10, and more potently IL-4, shift microglial cells towards an
increase of the arginase activity (Fig. 2C).
3.3. Jagged1-induced polarization
Since Notch ligands are expressed by neurons and astrocytes
(Elyaman et al., 2007; Sestan et al.,1999), the effect of Notch stimulation
on microglial cells by the soluble ligand Jagged1 was analyzed.
Stimulation of MMGT12microglial cells with the soluble ligand Jagged1
Fig. 3. Notch stimulation affects microglial cells behaviour. A. MMGT12 microglial cells
were treated with Jagged1 (1 μg/mL) and RNA extraction was realized after 6 h of
incubation. Real-time RT-PCR resultswere normalized using L27 as a reference gene and
are shown as average expression fold change (±SEM) values obtained from three
experiments, each conducted in independent cultures (n=3), respective mRNA in
control conditions. ⁎pb0.05, mRNA levels are signiﬁcantly different from the
corresponding control levels. B. Phagocytosis assay. MMGT12 microglial cells were
treated with Jagged1 (1 μg/mL) during 24 h. Data are corrected for the cell population
values and are expressed as mean±SEM values obtained from three experiments, each
conducted in independent cultures (n=3). Results are expressed relative to control
(Ctr=100%). ⁎pb0.05, ﬂuorescence levels are signiﬁcantly different from the
corresponding control levels.
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(1 μg/mL) enhanced IL-1β, NOS-II, and to a lesser extent CCL2 and CCR2
expression levels (Fig. 3A). The increase of Hes1 expression level after
Jagged1 treatment conﬁrmed that the Notch pathway was indeed
stimulated by the Notch ligand (Fig. 3A).
The phagocytic ability was increased by the soluble ligand Jagged1
compared to the control levels (Fig. 3B).
3.4. Oligomeric versus ﬁbrillar Aβ-induced polarization
In order to compare the behavior ofmicroglial cells in the presence of
Aβ to the characterized M1- or M2-like phenotypes, two different Aβ
forms have been analyzed. The ol-Aβ was obtained without previous
incubation, while the f-Aβ was obtained by an incubation of the
oligomeric form at 37 °C during 2 days (seeMaterials andmethods). The
ﬁbrillization of the Aβwas conﬁrmed by the thioﬂavine T assay (Fig. 4).
Primarymicroglial cells exposed to ol-Aβ (5 μM)were characterized
by high expression levels of IL-1β, IL-6, TNF-α, NOS-II, COX-2, and CCL2
(Fig. 5A, B). On the contrary, f-Aβ increased the pro-inﬂammatory
parameters to a much lesser extent compared to the oligomeric form.
CCR2, arginase1, and Mmr were more decreased by ol-Aβ than by f-Aβ.
Like in classical pro-inﬂammatory conditions (LPS and IFN-γ), Notch1
expression level was increased (also if not in a signiﬁcant manner),
while Hes1 and PPAR-γwere reduced by the two forms of Aβ (Fig. 5C).
Moreover, the phagocytosis capacity was decreased in the presence of
both forms of the peptide compared to the untreated cells (Fig. 5D).
3.5. The effect of oligomeric Aβ treatment on M2-like microglia
Compared to ol-Aβ alone, the pre-treatment with the anti-
inﬂammatory cytokine IL-10 (1 ng/mL) 1 h before ol-Aβ (5 μM)
Fig. 4. Veriﬁcation of the Aβ form by the Thioﬂavine T assay. The two forms of Aβ (ol-Aβ
and f-Aβ) were prepared as described (see Materials and methods). The Thioﬂavine T
assay was performed to assess the ﬁbrillization of Aβ after a pre-incubation at 37 °C of
the oligomeric form during 2 days. Data are expressed as mean±SEM values obtained
from three experiments, each conducted in independent assays (n=3). ⁎⁎pb0.01,
ﬂuorescence levels are signiﬁcantly different from the corresponding control levels.
Fig. 5. Aβ induces a M1-like polarization, but the levels differ between ol-Aβ and f-Aβ. A, B, C. Primary microglial cells were treated with ol-Aβ (5 μM) or f-Aβ (5 μM) and RNA
extraction was realized after 6 h of incubation. Real-time RT-PCR results were normalized using L27 as a reference gene and are shown as average expression fold change (±SEM)
values obtained from three experiments, each conducted in independent cultures (n=3), respective mRNA in control conditions. ⁎⁎pb0.01, ⁎pb0.05, mRNA levels are signiﬁcantly
different from the corresponding control levels. D. Phagocytosis assay. MMGT12microglial cells were treated with ol-Aβ (5 μM) or f-Aβ (5 μM) during 24 h. Data are corrected for the
cell population values and are expressed as mean±SEM values obtained from three experiments, each conducted in independent cultures (n=3). Results are expressed relative to
control (Ctr=100%). ⁎pb0.05, ﬂuorescence levels are signiﬁcantly different from the corresponding control levels.
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activation slightly enhanced IL-1β expression levels, strongly reduced
those of IL-6, and decreased this of TNF-α (Fig. 6A). The transcription
levels of CCR2 and arginase1 were increased (Fig. 6B). Notch1 and
PPAR-γ expression levels were not modiﬁed by the pre-treatment of
IL-10 1 h before ol-Aβ activation compared to ol-Aβ alone, while Hes1
was enhanced (also if not in a signiﬁcant manner) (Fig. 6C). Moreover,
in the same conditions, the phagocytosis ability was strongly
increased (Fig. 6D).
IL-4 (1 ng/mL) pre-treatment 1 h before ol-Aβ (5 μM) activation
reduced IL-1β, IL-6, and TNF-α transcription levels, while raised this of
NOS-II compared to ol-Aβ treatment alone (Fig. 7A). In the same
conditions,mRNA “alternative”genesarginase1,Ym(1/2), andFIZZ1were
increased (Fig. 7B). Moreover, Notch1 expression level was decreased,
while PPAR-γ mRNA was enhanced (Fig. 7C). IL-4 did not affect the
decrease of the phagocytic ability induced by Aβ (data not shown).
4. Discussion
Microglia, the standby cells for immune defense in the CNS, have a
reputation for exacerbating the neural damage that occurs in neurode-
generative diseases (Kreutzberg,1996). However, research over the past
few years has established that microglia do not constitute a single,
uniform cell population, but rather comprise a family of cells with
diversephenotypes, some that are beneﬁcial andothers that theCNS can
hardly tolerate and that are therefore destructive (Schwartz et al., 2006;
Butovsky et al., 2006; Butovsky et al., 2005).
In the present study, we have analyzed the phenotypes of
microglial cells induced by different stimuli using the terminology
that is well accepted for the description of different states of activation
in macrophages/microglia, M1 and M2 being the extremes of a
spectrum of phenotypes (Mantovani et al., 2004; Mantovani et al.,
2002).
In theﬁrst part of the study, our transcriptionproﬁle analysis clearly
shows that MMGT12 and primary microglial cells exposed to LPS or
IFN-γ are characterized bya pronounced pro-inﬂammatory phenotype
that is comparable to the classical M1-like state in macrophages.
Moreover, the phagocytic capacity is dramatically decreased. On the
other hand, microglial cells treatedwith IL-10 or IL-4 are characterized
by anti-inﬂammatory states, called respectively the M2-deactivated
state and the M2-alternatively activated. Phagocytosis is clearly
enhanced by an IL-10 treatment. These different states of microglial
differentiation reﬂect the complexity of these cells and their capacity
to differentiate towards a multitude of phenotypes depending on their
surrounding environment.
In order to complete the list of signature genes useful to understand
the phenotype that is acquired by microglia during the progression of
neurodegenerative diseases, we have included two novel genes pertain-
ing to theNotch pathway. As shown in our previous results (Grandbarbe
et al., 2007), under pro-inﬂammatory conditions (LPS or IFN-γ), Notch1
transcription is raised, while that of the correspondent effector Hes1 is
diminished, suggesting that Notch1 andHes1 could be seen as a M1 and
M2 signature genes respectively. Furthermore, for theﬁrst time, our data
Fig. 6. The effect of IL-10 on ol-Aβ-induced microglial activation. A, B, C. Primary microglial cells were treated with IL-10 (1 ng/mL) 1 h before ol-Aβ (5 μM) activation and RNA
extraction was realized after 6 h of ol-Aβ incubation. Real-time RT-PCR results were normalized using L27 as a reference gene and are shown as average expression fold change
(±SEM) values obtained from three experiments, each conducted in independent cultures (n=3), respective mRNA in ol-Aβ treated cells. ⁎⁎pb0.01, ⁎pb0.05, mRNA levels are
signiﬁcantly different from the corresponding control levels. D. Phagocytosis assay. MMGT12 microglial cells were treated with IL-10 (1 ng/mL) 1 h before ol-Aβ (5 μM) activation
during 24 h. Data are corrected for the cell population values and are expressed as mean±SEM values obtained from three experiments, each conducted in independent cultures
(n=3). Results are expressed relative to ol-Aβ treated cells (ol-Aβ=100%). ⁎pb0.05, ﬂuorescence levels are signiﬁcantly different from the corresponding control levels.
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show that IL-4 decreases Notch1 expression in MMGT12 and primary
microglial cells. Since an up-regulation of Notch1 is associated with pro-
inﬂammatory events (Grandbarbe et al., 2007; Monsalve et al., 2006),
the alternatively activated cells conﬁrm a phenotype that is at the
opposite side of a pro-inﬂammatory differentiation.
Since Hes1 is affected by a pro-inﬂammatory exposure, the effect of
the soluble Notch1-ligand Jagged1 on microglial cell differentiation
has been compared to theM1 andM2 phenotypes. Our data show that
MMGT12 microglial cells stimulated with the ligand present a gene
expression proﬁle that is only slightly different from a resting state
and that, for the expression of some genes, resembles that
characterized for IL-10. Moreover, in support of these results, the
phagocytic activity is strongly enhanced after Notch stimulation,
suggesting that the treatment of microglial cells with Jagged1 steers
them towards a similar M2-like state. In a normal brain, neurons can
communicate with microglia through the release of “calming inputs”
(e.g. fractalkine produced by neurons and its receptor on microglial
cells) (Cardona et al., 2006). Since microglial cells are tightly
integrated into a dense tissue, it seems reasonable that cell-contacts
betweenmicroglial cells and other cells of the CNS could be ameans to
inform themselves of their state and their surrounding environment.
The expression of Jagged1 by neurons or astrocytes (Elyaman et al.,
2007; Sestan et al., 1999) could serve tomaintain microglial cells in an
anti-inﬂammatory state. It has been shown that astroglial expression
of Jagged1 is modulated by inﬂammatory cytokine signaling (Elyaman
et al., 2007; John et al., 2002). An increased expression of Jagged1 on
astrocytes will thus inﬂuence the microglial phenotype towards a
deactivated M2-like differentiation.
In the second part of the study, we have analyzed the phenotype
that is acquired by microglial cells primed with two different forms of
the Aβ peptide. Our results show thatmicroglia exposed to oligomeric-
Aβ (ol-Aβ) present a pro-inﬂammatory M1-like phenotype that
closely resembles that induced by LPS treatment. The ﬁbrillar form
induces a similar response, also if withmuch lower amplitudes in gene
expression. It thus appears that the most toxic form of Aβ for neurons,
the oligomers (Lesne et al., 2006), is also the most potent activator of
microglial cells. Supporting the idea that Aβ generates a M1-like state,
the phagocytic capacity is decreased in the presence of both oligomeric
and ﬁbrillar forms. This diminished phagocytic ability, together with
the pro-inﬂammatory gene expression proﬁle acquired by microglial
cells, could explain the vicious circle that characterizes AD progression
and the subsequent Aβ accumulation. This self-sustained pro-
inﬂammatory environment will thus decrease the clearance of Aβ by
microglial cells and simultaneously increase the neuronal production
of the peptide (Sastre et al., 2006).
In the last few years, several groups have focused on the under-
standing of microglial cell phenotypes during AD progression. Recently,
Jimenez (Jimenez et al., 2008) shows evidence of a switch in the
activated microglia phenotype from alternative, at the beginning of Aβ
pathology, to a classical at advanced stage of the disease in amicemodel
of AD. Colton and collaborators (Colton et al., 2006) demonstrates that,
in AD patients and in mice models of AD and of cerebral amyloid
angiopathy, microglial cells exhibit a hybrid activation state that
includes characteristics of classical and alternative activation. Although
these results are conﬂicting, they show that during AD progression, it is
highly likely that microglial cells change their activation state as a
function of the disease and time. It iswell known thatmacrophagesmay
become refractory to inﬂammatory stimulation and shift towards an
anti-inﬂammatory state after prolonged exposure (Mosser, 2003).
Emerging evidence indicates that the same phenomenon can occur in
microglia. Persistent activation of cultured rat microglia with LPS
induces signiﬁcant alterations in the signaling network downstream
from the LPS receptor, and progressive down-regulation of TNF-α and
nitric oxide (NO) production (Ajmone-Cat et al., 2003; Cacci et al.,
2008). A similar process could occur in the presence of Aβ because this
peptide, when aggregating into ﬁbrils, shares receptors and intracellular
signaling cascades with LPS (Fassbender et al., 2004). Therefore, while
inducing a M1-like state immediately in their early oligomeric form, Aβ
in their aggregating formwill skewmicroglial cells towards a refractory,
or less activated phenotype. Thus, our results are in line with those of
Colton and co-workers, who describe the co-existence of these two
phenotypes in the in vivo situation.
Finally, we were interested on the phenotype of microglial cells
pre-treated with anti-inﬂammatory cytokines before ol-Aβ activation.
It is known that microglia respond differently to the same stimulus
Fig. 7. The effect of IL-4 on ol-Aβ-induced microglial activation. A, B, C. Primary
microglial cells were treated with IL-4 (1 ng/mL) 1 h before ol-Aβ (5 μM) activation and
RNA extractionwas realized after 6 h of ol-Aβ incubation. Real-time RT-PCR results were
normalized using L27 as a reference gene and are shown as average expression fold
change (±SEM) values obtained from three experiments, each conducted in
independent cultures (n=3), respective mRNA in ol-Aβ treated cells. ⁎⁎pb0.01,
⁎pb0.05, mRNA levels are signiﬁcantly different from the corresponding control levels.
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depending on whether other stimuli precede or follow it, suggesting
that behavior of microglia is dictated by an acquired phenotype rather
than stereotypically (Schwartz et al., 2006). It has been shown that IL-
10 or IL-4 are able to reduce the microglial pro-inﬂammatory state
induced by Aβ (Lyons et al., 2007; Szczepanik et al., 2001). Our data
show that microglia activated with even low doses of IL-10 or IL-4
remain affected by these treatments evenwhen they were exposed to
a threatening environment in the form of themore potent ol-Aβ. Since
the normal aging of the human brain is characterized by an increase in
the expression of pro-inﬂammatory cytokines (Ye and Johnson, 1999)
along with a decrease of anti-inﬂammatory cytokines, such as IL-10
(Ye and Johnson, 2001) and IL-4 (Maher et al., 2005; Nolan et al.,
2005), it is to be expected that senescent microglial cells will be more
easily skewed towards a M1-like phenotype in the presence of newly
synthesized oligomers of Aβ than young ones.
Taken together, our results clearly emphasize that the variability of
microglial activity is not merely a reﬂection of stimulus strength or
persistence. Rather, it is determined largely by the nature and context
of the stimuli and the intracellular signal transduction pathways that
they activate.
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